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1. Introduction 
In view of from recent advancements, in a time of augmented remarks to the efficacy and 
safety of the medicines embedded in dosage forms, it seems as important as ever to study 
the pharmaceutical concept of the latter in different aspects, prerequisite for a successful 
pharmacotherapy.  
Despite tremendous advancements in drug delivery, oral administration of therapeutic 
agents still remains the favored rout for majority of clinical applications, due to the excellent 
accessibility, and patient compliance as well as the preferred alternative route of drug 
administration for non-invasive drug delivery among the other various routes [Motlekar & 
Youan, 2006]. Although there have been several limitations in oral administration of drugs 
like non-uniform drug absorption profiles, incomplete drug release, shorter residence time 
of dosage forms in absorption window and etc. to systemic circulation it has come a long 
way. Now, it has turned towards modifying and manipulating oral dosage forms to exploit 
from different conditions of the gastrointestinal (GI) tract for drug delivery in various ways 
[Hirtz, 1985]. 
In view of the fact that the correlation between drug intake and a clinical response is 
complex enough, the choice and design of the ideal pharmaceutical dosage form of a drug 
delivery system would be critically important to reach a progress in superior drug 
development. Variations between drug response within individuals could be attributed 
either to product bioavailability (like the rate and extent of drug absorption), drug 
pharmacokinetics (which includes the metabolism, distribution, and elimination of a drug), 
or the particular concentration-effect relationship, which in turn could potentially be 
influenced through a mixture of intrinsic and extrinsic variables [Hirtz, 1985; Martinez & 
Amidon, 2002; Javadzadeh et al., 2010]. 
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With reference to the Biopharmaceutical Classification System, introduced by the Food and 
Drug Administration (FDA) in 1995, drugs have been categorized in terms of their solubility 
and intestinal permeability in four primary groups (Figure 1). 
 
Figure 1. The Biopharmaceutical Classification System (BCS) as defined by the FDA 
Drugs that are categorized in class one (BCS 1) are supposed to be well absorbed when 
taken orally, due to their high solubility and high permeability characteristics. Whereas, all 
other drugs in BSCs 2 to 4 suffer from low solubility, low permeability or both, and would 
present challenges to the drug developments. Drugs that are classified in low solubility 
groups keep drug absorption via the GI tract as the limiting factor for reaching in suitable 
blood-levels of drugs [Martinez & Amidon, 2002; Javadzadeh et al., 2007).  
As far as we know, absorption of drugs from intake (e.g., oral delivery systems) to its site of 
action is a complex process, or more accurately, a combination or succession of complicated 
processes which is schematically presented in Figure 2.  
After oral administration, drug leaves the formulation and dissolves in the aqueous 
digestive fluids. It reacthes and crosses the GI mucosal membrane before passing into blood, 
moving along the GI tract with the luminal content at a variable speed. Once the drug is 
reached into the blood circulation, processes of drug metabolism and elimination starts, 
whilst, it is also possible for some drug degradation or metabolism to occur sooner than the 
absorption is completed leading for a decrease in drug efficiency [Riley et al., 1992]. 
In general, absorption of drugs through GI tract varies on account of many factors like the 
nature and surface area of the GI mucosal membrane varying from the stomach to the 
rectum, as well as the physicochemical properties of the pharmaceutical dosage form along 
with the luminal content. Hence, a balance among these factors would have a notable effect 
on how much of the administered drug reaches to the bloodstream that is summed up by 
the term bioavailability. Considering the pharmacokinetics and disciplines of drug 
discovery and drug delivery, it has become obvious that a deep understanding of the 
biology and anatomy of the GI tract is of substantial value for optimizing the bioavailability 
of orally administered drugs. 
BCS  1 BCS  2
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Figure 2. Schematic representation of the relationship between an oral dosage form of a drug and its 
ultimate effect. 
2. GI anatomy and dynamics 
GI tract is a group of organs joined in a long tube which is divided into several sections, 
each of that fulfills a specific function. The tract begins with oral cavity, follows pharynx, 
esophagus, stomach, small intestine and large intestine ending with rectum to anus part 
(Figure 3). 
Each segment has certain morphological and physiological features, but there is almost a 
common structure for all parts of GI with muscular walls comprising four different layers: 
inner mucosa, submucosa, muscularis externa, and the serosa.  
Stomach serves the most primarily mixing area and a reservoir that secretes pepsinogen, 
gastric lipase, hydrochloric acid, and the intrinsic factor. This section of the GI tract is 
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normally impermeable for absorption of most materials into the blood except water, ions, 
alcohol, and certain drugs such as aspirin. It follows small intestine, the major digestive and 
absorptive site of the GI tract, providing an extended surface area by the circular folds of 
about 10 mm height through the microvilli on the absorptive cells of the mucosa. The last 
part of the GI tract is the large intestine extending from the ileum to the anus with 1.5 m 
long and 6.35 cm in diameter serving mainly the fecal storage and water absorptive roles. It 
is significant that no enzymes are secreted in the mucosa, and the last stage of digestion is 
primarily conducted by the resident bacteria [McConnell et al., 2008]. 
 
Figure 3. Anatomy of the human gastrointestinal tract [Friend & Tozer, 1992). 
Not surprisingly, these anatomical and physiological parameters of the GI tract remarkably 
affect the rate and level of drug absorptions and should be assessed. There are several 
difficulties and rules in designing controlled release systems to be considered for better 
absorption and enhanced bioavailability of drugs embedded in the orally administered 
dosage forms. One principal requisite for the successful performance of orally administered 
drugs is that the drug should have good absorption throughout the GI tract, to certify 
continuous absorption of the released drug [Davis, 2005]. Regarding the BCS classification 
of drugs, this could be a major constraint in oral controlled drug delivery systems that not 
all drugs are evenly absorbed throughout the GI tract. Seeing as, most of the orally 
administered drugs display region-specific absorption that could be related to differential 
drug solubility and stability in different regions of the GI tract as a result of changes in 
environmental pH, degradation by enzymes present in the lumen of the intestine or 
interaction with endogenous compounds (Table 1). Furthermore, drugs that are substrates 
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of certain enzymes in particular regions of the GI tract might have regional variability in 
their absorption along the GI tract. One should consider this region specific drug absorption 
concept for designing the ideal drug formulation. It has been widely accepted that about 
90% of all absorption of nutrients takes place in the small intestine, and the rest occurs in the 
stomach and large intestine, depending on the defining characteristics of GI fluids and 
membrane surface area at different locations [Davis, 2005]. Consequently, transit time of a 
pharmaceutical dosage form through the GI tract would determine how long a drug will be 







pH Major constituents 
Transit 
time (h) 
Oral cavity 15- 20 10 
5.2- 
6.8 
Amylase, Maltase, Ptyalin, Mucins Short 
Esophagus 25 2.5 5- 6 - Very short 
Stomach 20 15 
1.2– 
3.5 
Hydrochloric acid, Pepsin, Rennin, 
Lipase, Intrinsic factor 
0.25- 3 
Duodenum 25 5 
4.6– 
6.0 
Bile, Trypsin, Chymotrypsin, Amylase,
Maltase, Lipase, Nuclease, CYP3A4 
1- 2 
Jejunum 300 5 
6.3– 
7.3 
Amylase, Maltase, Lactase, Sucrase, 
CYP3A5 
- 
Ileum 300 2.5- 5 7.6 
Lipase, Nuclease, Nucleotidase, 
Enterokinase 
1- 10 




Colon 150 5 
7.9 - 
8 
- 4- 20 




Table 1. Anatomical and physiological features of the human GI tract 
The usual transit time for a drug formulation or for a nutrient to pass from the stomach to 
the ileocecal valve (through the small intestine) is around three hours and transit time for 
colon is much longer up to twenty hours or more. Subsequently, the time a drug will have in 
its absorption site would be fairly short, more so if the drug is preferentially absorbed in the 
proximal small intestine rather than throughout the small intestine. Accordingly, a drug that 
is largely or solely absorbed from the upper GI tract would have variable bioavailability 
distressed by factors that change GI transit. Moreover, GI transit time of a drug formulation 
as the most limiting physiological factor in the development of oral drug delivery systems 
might be altered by the physiological properties of the GI tract too. The patterns of GI transit 
and gastric emptying depend on whether the person is in a fasted or fed state, and the 
physical state of the drug delivery system, either a solid or a liquid form [Bode et al., 2004]. 
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Gastric emptying of liquids in the fasted state is a function of the volume administered, 
whereas, indigestible solids are emptied from the stomach as a function of their physical 
size [Bardonnet et al., 2006; Khobragade et al., 2009].  
There also exist several issues affecting motility of the GI tract such as systemic disease, 
drug therapy and intrinsic GI disorders. Diabetes, idiopathic intestinal muscle disease, 
Chaga's disease, muscular dystrophy, gastroparesis and etc. are characterized by delayed 
gastric emptying and a reduction in GI motions. On the contrary, in the case of diarrhea, 
infectious diseases, thyrotoxicosis and irritable bowel syndrome an increased GI motion is 
usually detected [McConnell, Fadda et al., 2008]. Even though, increasing the rate of gastric 
emptying and GI motility increases the rate of drug absorption, for digoxin and riboflavin, 
increased GI motility is associated with a decrease in the rate of drug absorption. It is of note 
to be reminiscent of the fact that, a failure in therapeutic efficiency of drugs is inevitable due 
to the delayed drug absorption issued from altered gastric emptying if the drug has a short 
biological half-life.  
Anticholinergic medications, tricyclic antidepressants, levodopa, and β-adrenergic agonists 
are famous groups of medicine that suppress GI motility. Alternatively, drugs that enhance 
GI motility by increasing contractile force and accelerating intraluminal transit are called 
prokinetics like metoclopramide, cisapride, tegaserod, and erythromycin (macrolide 
antibiotic). Other groups of medical preparations (proton pump inhibitors, antacids, histamine 
receptors type 2 antagonists, etc.) that are used to treat a wide variety of stomach and 
duodenal diseases associated with hyper-acidity by raising the intragastric pH would alter the 
pH-dependent solubility and stability level of a certain kind of drugs administered orally. 
Most drugs are absorbed via passive diffusion of the nonionized form, so the amount of 
ionization at the different physiological pH values encountered in the GI tract would bring 
about non-uniform drug absorption and bioavailability [McConnell, Fadda et al., 2008]. 
Although it is not possible to predict accurately the magnitude and clinical relevance of all 
drug absorption interactions through the GI tract, designing a suitable dosage form that 
would function independent of the digestive state, clinical condition, or GI motility of the 
individuals is an imperative fundamental of the drug delivery system dominating these 
constraints. So the important requisite for the successful performance of oral drug delivery 
systems is that the drug should have good absorption throughout the GI tract. Since, all the 
orally controlled-release drug delivery systems would show limited utilization in the GI 
controlled administration of drugs if the systems cannot remain in the absorption site for the 
lifetime of the dosage form, establishing a prolonged GI transit time of orally administered 
drugs appears to be logical.  
3. Prolongation of GI retention 
It is clear from the recent scientific literatures that an increased interest among the academic 
and industrial research groups still exists in formulating novel dosage forms that are 
retained in the stomach for a prolonged and predictable period of time.  
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The most feasible method for achieving a prolonged and predictable drug delivery in the GI 
tract is to control the gastric residence time by gastro retentive and sustained release dosage 
forms that have some beneficial in safety and efficacy over normal release systems. This 
method of application is especially helpful in delivery of sparingly soluble and insoluble 
drugs. It is acknowledged that, as the solubility of a drug decreases, the time available for 
drug dissolution becomes less adequate and so the transit time becomes an important factor 
affecting drug absorption in drugs with lower solubility. Other drug candidates suitable for 
gastroretentive drug delivery systems include those drugs that are locally active in the 
stomach, drugs with narrow absorption window in GI tract, drugs that are unstable in the 
intestinal or colonic environment, drugs that act locally in the proximal part of GI tract or 
disturb normal colonic microbes like antibiotics and also drugs that exhibit low solubility at 
high pH values. Concerning the pharmacotherapy of the stomach through local drug release 
of gastroretentive dosage forms, bringing about high levels of drug concentrations at the 
gastric mucosa (eradication of Helicobacter pylori from the submucosal tissue of the stomach), 
and treating stomach and duodenal ulcers, gastritis and oesophagitis, the risk of gastric 
carcinoma would be drastically reduced. In contrast, there are drugs that do not fit in 
gastroretentive drug delivery systems; Drugs that have very limited acid solubility, drugs 
that suffer instability in the gastric environment, and drugs intended for selective release in 
the colon should follow other techniques of drug delivery to reach for their intended site of 
action. Hence, gastroretentive dosage forms despite providing rather constant drug 
concentrations in the bloodstream for longer periods of time do not fulfill this benefit with 
several groups of drugs. 
One of the advantages of the sustained release dosage forms is that medication are 
administered less often than other dosage forms reducing fluctuations of drug concentration in 
the bloodstream. As a result, patients are not repeatedly subjected to different levels of drug 
which are less or more than adequate. Nor does the blood chemistry undergo frequent 
chemical imbalances, which might be risky to the patient's health. Additionally, through 
gastroretentive dosage forms not only the bioavailability and therapeutic efficacy of drugs are 
improved but also it may allow for a possible reduction in the dose because of the steady 
therapeutic levels of drugs. Drugs that have poor solubility in higher pH, absorption windows 
in stomach, and the ones requiring locall delivery in stomach could be delivered ideally to the 
site of action by these gastroretentive formulations. On the other hand, drugs that cause 
irritation to gastric mucosa and the ones meet first-pass metabolism or have stability problems 
in gastric fluids are not appropriate for these kinds of drug delivery systems.  
In brief, gastric retention is a means to enable a delivery strategy that will function irrespective 
of the digestive state, clinical condition, or GI motility of the individuals with longer drug 
residence time in the stomach being advantageous in superior drug bioavailabilities and also 
in certifying local action of some drugs in the upper part of the GI tract. Various approaches 
that have currently become leading methodologies for increasing the resistance time of a 
dosage form in the stomach would be highlighted in this section forward. Nevertheless, the 
early reports on gastroretentive systems have been well-reviewed in pervious literatures, only 
the more recent development and strategies will be discussed here. 
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3.1. Intragastric floating drug delivery systems 
3.1.1. Introduction 
Design of floating pharmaceutical dosage forms with a bulk density less than gastric fluid is 
one of the thriving trends for enhancing drug residence in the stomach. These systems 
would act independent of the highly variable nature of the gastric emptying process 
resulting in reduced fluctuations of drug bioavailabilities.  
Apart from the commented benefits established by these floating systems, they could also 
have their limitations given that they require a satisfactory level of fluid in the stomach to 
float. Likewise, in the fed state a change in body position to supine could have a direct effect 
on the floating system. In order to design a more systematic and intellectual floating system 
it is as important as ever to study different aspects of these systems to have a deeper insight 
to the buoyancy, drug release mechanisms, effectiveness and reliability of these floating 
systems as an strategy for establishing an efficient gastroretentive drug delivery system 
[Blanquet et al., 2004]. 
In this regard, different approaches have been followed to support the buoyancy of dosage 
forms in the stomach. Based on the mechanism of floatation, two obviously different 
technologies are employed in development of floating dosage forms, effervescent and non-
effervescent systems 
3.1.2. Effervescent systems 
These buoyant systems are usually matrices of swellable polymers along with effervescent 
components that generate carbon dioxide (CO2) entrapped in swollen hydrocolloids of the 
dosage forms. In these systems floatation is achieved through the incorporating of a gas 
within the formulation lessoning density of the system and making it float on the gastric 
fluids [Krogel & Bodmeier, 1999; Sungthongjeen et al., 2008].  
Acid - base reactions have been utilized for decades to produce various pharmaceutical 
preparations which effervesce as contacting with water. Sources affording the acidity in 
effervescent reactions are essentially provided by acids, acid anhydrides, and acid salts 
where organic acids, citric and acetic acids are the most commonly used materials. In 
contrast, carbonates and bicarbonates in contact with acids are used typically as CO2 
generation sources. Carbonates not only play critical role in making the dosage form 
buoyant but also provide the initial alkaline micro environment for the polymers to gel 
[Sungthongjeen, Sriamornsak et al., 2008; Patel et al., 2009; Rajab et al., 2010]. These carbon 
dioxide generating components could be intimately mixed within the matrix to produce a 
single-layered dosage form or a multi-layered formulation which might contain the gas 
generating mechanism in one hydrocolloid containing layer and the drug in the other layer 
formulated for the sustained release effect (Figure 4). The matrices are fabricated so that 
upon contact with gastric fluid, carbon dioxide is liberated with an upward motion of the 
dosage form maintaining its buoyancy in the gellified hydrocolloid. Totally, the reaction is 
due to the CO2 generated by neutralization in the effervescent layer with the diffusion of 
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water through the swellable membrane layer. However, there may be a lag time relying on 
the duration of gas generation reaction that could end in gastric emptying of the dosage 
form before floatation. More reliable gastric emptying patterns are attained for multi 
particulate formulations consisting loads of small discrete units as compared with single 
unit formulations containing one unit suffering from “all or none concept” [Sungthongjeen 
et al., 2006]. These multi particulate formulations are also better distributed in the GI tract 
and are less likely to cause local irritation. Recently, much more emphasis is being laid on 
the development of multi particulate dosage forms rather than single unit systems to their 
potential benefits like increased bioavailability, reduced risk of systemic toxicity, reduced 
risk of local irritation and predictable gastric emptying manners.  
 
Figure 4. Mechanism of action in effervescent floating drug delivery system. 
This view is supported by a variety of papers developing effervescent systems using 
different polymers and drugs, all agreed in the practicality and feasibility of the approach. 
In this regard, Pahwa et al. formulated effervescent floating tablets of famotidine with an 
effective and safe therapy for stomach ulcers in a reduced dose manner [Pahwa et al., 2012]. 
Hydroxypropyl methylcellulose K15M and hydroxypropyl methylcellulose K100M as gel 
forming agents along with sodium bicarbonate and citric acid as gas generating agents were 
used in the research. Concerning the results of the study, it was concluded that the addition 
of gel-forming polymers, methocel and gas generating agent, sodium bicarbonate along 
with citric acid were essential to achieve in vitro buoyancy profile. Faster and higher CO2 
generation caused by increasing the concentration of effervescent agents resulted in higher 
swelling of polymeric membrane according to a higher gas pressure [Pahwa, Chhabra et al., 
2012]. Additionally, expansion of the hydrated matrices increased the surface area available 
for dissolution and presence of gas bubbles hindered the diffusion path, decreasing the 
release constant values. Concisely, in these systems generation of the CO2, entrapped in the 
matrix is the constant principle rule that has been widely established in studies of this 
category. 
3.1.3. Non-effervescent systems 
Non-effervescent systems incorporate a high level of one or more gel forming, highly 
swellable, cellulosic hydrocolloids, poly saccharides or matrics forming polymers into the 
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formulations employing no gas forming agents during the procedures. These gel formers, 
polysaccharides and polymers hydrate in contact with gastric fluids and form a colloidal gel 
barrier resulting in the floatation of the dosage form. Practical approaches in formulating 
non-effervescent floating dosage forms are listed below. 
3.1.3.1. Hydrodynamically Balanced Systems (HBS) 
The HBS systems are developed with gel-forming hydrocolloids forming a hydrated gel 
layer in the outer exposed surface of the dosage form on contact with gastric fluids 
imparting buoyancy for a long period of time. Gel-forming or highly swellable cellulose 
type hydrocolloids such as hydroxypropyl cellulose, hydoxyethyl cellulose, hydroxypropyl 
methyl cellulose, polysaccharides, matrix forming polymers and the drug that is with gel-
forming hydrocolloids are homogeneously thoroughly mixed within the HBS formulations 
[Khattar et al., 1990; Dorozynski et al., 2004]. Hydration of the inner layers brings about 
surface hydration and a soft gelatinous barrier around the dosage form. This soft gelatinous 
mass on the surface of the formulation provides a water-impermeable colloid gel barrier on 
the surface of the tablets. Consequently, the hydrated gel controls the rate of water 
penetration into the dosage form and the rate of drug release from the HBS. Different 
varieties of polymers could be utilized in the floating drug delivery systems as well in the 
HBS. Kumar et al. studied effect of different excipients and polymers on floating behavior 
and drug release from floating HBS matrices. It was found that the selection of suitable 
excipients depending on polarity of drug modulates the floatability and drug release 
profiles where water uptake in the floating matrix increased with the increase in the loading 
of polar drugs and decreased with non-polar drugs [Kumar et al., 2004]. Elsewhere, a 
hydrodynamically balanced delivery system of clarithromycin was developed by Nama et 
al. to prolong gastric residence time with a desired in vitro release profile for the localized 
action in the stomach, with the intention of Helicobacter pylori mediated peptic ulcer 
treatment. Different kinds of polymers with various possible concentrations were assessed 
to establish the optimum formulation with 66.2% clarithromycin, 12% HPMC K4M polymer, 
8% sodium bicarbonate offered improved floating lag time less than 3 min and 12 h duration 
of floating [Nama et al., 2008]. 
In general, use of HBS is desirable which swell to create a gel-like structure after 
administration and attain a density less than that of gastric fluids where a prolonged drug 
delivery is required. Not many practical reports were found on the non-effervescent HBS 
drug formulations as compared to the effervescent systems. As a matter of fact, considering 
the all or none gastric emptying of HBS dosage forms, development of floating drug 
delivery system using multiple-unit devices to distribute uniformly within the gastric 
content and gradually pass through the GI tract still is one of the challenges in this field.  
3.1.3.2. Porous systems 
Porous materials are emerging day by day as a new category of drug delivery systems due 
to the several alternative features such as stable uniform porous structure, high surface area, 
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and tunable pore sizes with narrow distribution and well defined surface properties. Theses 
porous carriers have been playing one of the key roles in the pharmaceutical industries 
including development of novel drug delivery systems such as floating and sustained drug 
delivery systems in improving the solubility of poorly water soluble drugs [Ahuja & Pathak, 
2009; Sher et al., 2009]. Porous structures such as silica, porous ceramic, ethylene vinyl 
acetate, polypropylene foam powder and titanium dioxide allow the inclusion of drugs 
inside a porous compartment possessing a relatively lower density than the gastric juice 
thus remaining buoyant in the stomach [Streubel et al., 2002]. This approach of flotation is 
based on the principle of the encapsulation of a drug reservoir inside a microporous 
compartment with pores along its top and bottom walls. Any other polymer that may be 
added to the dosage form would moderately cover the pores and entrap air within the 
system. However, the peripheral walls might get completely sealed to prevent any direct 
contact of the gastric surface with the drug bringing about delayed release of drugs. Besides, 
the entrapped air would gradually removed from the formularion in exposure to gastric 
medium, leading to an extended floating times with a more reproducible and predictable 
drug release manner. After all, interests and notable surveys have been directed in recent 
years towards the porous carriers as controlled drug delivery matrices. 
A multi particulate floating delivery system, consisting of highly porous carrier material 
calcium silicate, glipizide as the drug, and eudragit S as the polymer, was developed by 
Pandya et al. Glipizide as a second-generation sulfonylurea with short biological half-life (3-
4 h) and the site of the absorption in the stomach was an excellent candidate for 
development of controlled-release dosage forms that are retained in the stomach increasing 
the absorption, drug efficiency, along with decrease in dose requirements. In this regard, 
they evaluated effects of various formulation variables on the internal and external particle 
morphology, micromeritic properties, in vitro floating behavior, and in vitro drug release. 
The designed system, showed excellent buoyancy and suitable drug release pattern, 
possibly being advantageous in terms of increased bioavailability of glipizide over an 
extended period of time [Pandya et al., 2011]. 
More recently, Yao et al. developed a simple and rapid method of floatation to prepare a 
novel kind of inner-porous floating beads using foam solution using poloxamer 188 as 
foaming agents and alginate as foaming stabilizer. Riboflavin, a water-soluble vitamin was 
used as a model drug which has a narrow absorption window in the upper part of the 
intestine and a saturable absorption mechanism. In this method poloxamer 188 was used as 
an effective amphiphilic surfactant which could lower the water surface tension 
significantly. In addition, foam solution was formed by stirring in the presence of poloxamer 
188, winding microbubbles in the alginate and stabilizing the foam solution. Findings of the 
study revealed that addition of the non-ionic surfactants poloxamer 188 lead to the 
formation of a surfactant–polymer complex through interactions between polymer and 
surfactant contributing in the foamability and foam stability of the formulations. Moreover, 
higher concentration of the poloxamer 188 increased the foamability and foam stability of 
the mixed solution. These results were verified through scanning electron microscopy cross-
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section pictures of the beads showing inner-porous with fully bubbled nature of the beads 
with very thin wall bubbles stacked together. Additionally, gamma scintigraphic images 
and pharmacokinetic studies in vivo showed that the beads could retain in the stomach for 
over 6 h and improved bioavailability of the drug [Yao et al., 2012]. 
3.1.3.3. Alginate beads 
Lately, both natural and synthetic hydrophilic polyionic systems like alginates have been a 
center of attention for preparation of floating systems. The interest in alginates is chiefly due 
to their high biocompatibility and nontoxic nature in oral administration that also 
demonstrate protective effect on the mucous membranes of the upper GI tract. Alginate 
beads with the structure of spherical gels are taken shaped through dropwise addition of 
aqueous alginate solution to the aqueous solution containing calcium ions and/or other di 
and polyvalent cations [Javadzadeh et al., 2010]. The pH dependent reswelling property of 
dried alginate beads let them to be administrated as a unique vehicle as the multi unit 
floating dosage forms in GI tract as early as 1980s [Murata et al., 2000].  
In recent years, the amount of literature published on development of these alginate beads 
providing satisfactory data for a variety of applications has been grown remarkably. In a 
study, cinnarizine, a piperazine derivative as a Ca channel blocking and anti- histaminic 
drug suffering from incomplete and variable oral absorption which occurs mainly in the 
proximal small intestine was formulated as a floating multiple unit dosage form of alginate 
beads. Ghareeb et al. formulated floating cinnarizine olive oil-entrapped emulsion gel beads 
by the emulsion–gelation method. They came into conclusion that formulation variables 
greatly influenced the mean particle size and in vitro drug release characteristics of the 
prepared beads. Ultimately, the experimental observations suggested cinnarizine loaded 
alginate beads could potentially be useful in drug delivery systems for making controlled 
release gastroretentive floating beads of drugs via the ionotropic gelation technique 
[Ghareeb et al., 2012]. Furthermore, in our previously published paper, we prepared floating 
beads of metronidazole via the ionotropic gelation method employing gas forming (sodium 
bicarbonate) and porous (calcium silicate) agents followed by a physicochemical 
evaluations. It was found that the kind and amount of agents used to make the beads 
floated, i.e., sodium bicarbonate and calcium silicate, had a profound effect on the beads 
size, morphology, and floating ability as well as drug release profile [Javadzadeh, 
Hamedeyazdan et al., 2010]. In general, high compatibility of the alginate beads in achieving 
a suitable floating dosage form controlling the drug release from the beads with a definite 
kinetic of release was clear enough to be supported.  
Novel prospects for application of floating alginate beads were accomplished by emphasizes 
on advantages and future potential of probiotic loaded beads in the treatment of GI 
disorders. As we know, probiotics are live microbial feed supplements that beneficially 
affect the host by improving its intestinal microbial balance that may undergo antagonistic 
interactions with pathogenic bacteria. However, significance of probiotics survival in the GI 
tract, their translocation, colonization and the fate of probiotic derived active components 
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indicate a need and scope of packaging them into a suitable delivery system to increase the 
viability of the probiotics, both outside and inside the body. Singh et al. developed a floating 
drug delivery system of Lactobacillus acidophilus via orifice ionic gelation method in alginate 
beads. They evaluated the efficacy of the approach in experimental model of cold restraint 
stress induced gastric ulcer in terms of ulcer index; hemorrhagic streak length; mucus 
content and histopathological examinations. According to the authors, the developed 
formulations not only efficiently protected the entrapped probiotic cells, but also effectively 
delivered and retained viable bacteria in the stomach [Singh et al., 2012]. The prolonged and 
continuous release of the probiotic in the gastric mucosa allowed them for an ensured 
therapeutic efficacy of the developed floating system against ulcers post-induction, thus 
suggesting an efficient line of treatment. 
3.1.3.4. Hollow microspheres / microballoons 
One of the renowned approaches in devising multiple unit floating systems are the hollow 
microspheres (microballoons), spherical empty particles without core that are designed to 
float on gastric juice [Gholap et al., 2010]. Hollow microspheres incorporating a drug 
dispersed or dissolved throughout particle matrix have the potential for controlled release 
of drugs. These microspheres are characteristically prepared by solvent diffusion and 
evaporation methods where the relative polymer is dissolved in an organic solvent and the 
drug dissolved or dispersed in the polymer solution is emulsified into an aqueous phase 
containing suitable additive (surfactants / polymer) to form oil in water emulsion (Figure 5). 
After removal of the organic solvent, polymer precipitates at the oil/water interface of 
droplets, forming cavity and thus making them hollow to impart the floating properties. 
Frequently used polymers in developing hollow microspheres are polycarbonate, chitosan, 
methocil, polyvinyl acetate, carbopol cellulose acetate, calcium alginate, eudragit, agar and 
also pectin [Soppimath et al., 2006].  
In general, hollow microspheres are believed to be prominent buoyant systems as they 
provide a multi-unit system with an improved floating property. This view is supported by 
scores of reports on development of the emulsion solvent diffusion method to form hollow 
microspheres employing different polymers and drugs to follow a promising drug delivery 
system floating on the gastric juice. Rosiglitazone hollow microspheres were prepared 
through modified quasi-emulsion solvent diffusion method by Gangadharappa et al. to 
improve the oral hypoglycemic agent’s bioavailability. The formulated dosage form 
controlled the drug release, avoiding dose dumping, in an extended floating duration 
[Gangadharappa et al., 2011]. Elsewhere, Rane et al. prepared hollow microspheres of 
rosiglitazone were by O/W emulsion-solvent diffusion technique using biodegradable 
anionic acrylic resin as a polymer. They provided evidence that a modification of external 
aqueous phase with salt (CaCl2 and NaCl) improved the drug entrapment efficiency for 
moderately soluble drug by 45–50% as a result of salting out effect. Predominantly, the 
release mechanism for formulations was diffusion controlled and followed the first order 
kinetics [Rane et al., 2012].  
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Figure 5. Solvent diffusion and evaporation technique in formation of the hollow inner core 
microspheres. 
3.1.4. Physicochemical evaluations 
In development phase for floating dosage forms, designing a selection of suitable control 
principles is of crucial importance. This would be beneficial in preventing the development 
efforts to costly late stage product failures throughout the manufacture and administration 
periods too. Besides, health authorities worldwide necessitate accurate adjustment of the 
physicochemical parameters of the formulation for all individually administered dosage 
forms in advance to clinical phase [Parikh & Amin, 2008]. 
3.1.4.1. In vitro buoyancy and drug release properties 
Not surprisingly, insufficient and inconsistent formulation buoyancy, drug dissolution and 
the subsequent inadequate drug efficacy are some of the routine challenges to be coped with 
during the development of floating drug delivery systems when they are administrated 
orally. It is of essential for these kinds of dosage forms to have a satisfactory floating 
activity, for giving the drug a chance for sufficient dissolution rate, absorption, and a 
suitable clinical efficacy, as well. Since, different physiological situations may affect the 
results for buoyancy and dissolution and drug release from pharmaceutical dosage form, in 
vitro tests for buoyancy and drug release studies are usually carried out in close proximity 
to the physiological conditions of the human body to lessen the variation derive from 
altered dissolution medium. The apparatus and procedures of USP are preferred the best to 
make a better correlation between in vitro and in vivo results of the floating and drug 
release tests. Generally, the tests are determined in 900 mL of simulated gastric fluid 
(HCl/NaCl with 0.02% Tween 80, pH 1.2) maintained at 37°C using basket or paddle stirring 
elements of the USP dissolution apparatus [Mudie et al., 2010]. Besides, the time needed for 
 
Novel Drug Delivery Systems for Modulation of Gastrointestinal Transit Time 407 
the dosage form to float and duration of the buoyancy are noted as the floating lag-time and 
flotation time are evaluated as the floating behavior of the formulations.  
There have been numerous published reports on diverse challenges of the floating drug 
delivery systems applying a variety of floating agents to encourage buoyancy of the 
pharmaceutical dosage forms with a controlled drug release. Gupta at al. prepared floating 
microspheres of clopidogrel bisulfate using different viscosities of ethyl cellulose and 
triethyl citrate as a plasticizer using emulsion solvent diffusion technique. It was detected 
that the drug release from the floating microspheres matrix was completely controlled by 
the polymer as the polymer proportion in the formulation was increased, a decrease in drug 
loading, drug release was observed. The floating ability of different formulations was found 
to be altered according to polymer ratio. Overall, the prepared formulations showed 
appropriate balance between buoyancy and drug release rate dependent on the amount of 
formulation variables [Gupta & Rajpoot, 2012]. Most of the relative papers dealing with the 
development and optimization of the buoyancy lag time and duration of drug release 
employed both swellable polymers and gas generating systems to increase the buoyancy 
and lag times. Several studies in this filed have shown that different factors influence the 
buoyancy and drug release from a pharmaceutical dosage form and contributing in different 
patterns of drug release in similar floatation preparation methods.  
Accordingly, different factors influence the buoyancy and drug release from a 
pharmaceutical dosage form. Solubility of the drug in dissolution medium as well as the 
formulation variables in the dosage form are the dynamic items, contributing distinctively 
in drug release differences of the floating dosage forms with similar basic floatation 
preparation methods. It has always been a great challenge to modify the drug release in an 
expected manner and assess the efficiency of the dosage form in an in vivo environment. 
Even if the more or less standardized in vitro methods described in the pharmacopeial 
monographs are used in different studies, the correlation between in vivo and in vitro 
results must be confirmed from case to case in individuals prior to the clinical application. 
3.1.4.2. In vivo assessments 
Very early on, in the development phase of drugs a reliable relationship has to be 
established between in vitro and in vivo test, in order to expose therapeutically relevant 
discrepancies first between different formulations and later also between drug production 
batches. This correlation is most likely if the test conditions are in close proximity to the 
physiological circumstances. Hardly ever, do the in vitro assessments fully counterpart the 
in vivo results, since the standard USP methods have not been a reliable predictors of in 
vivo performance of the floating pharmaceutical dosage forms [Kaus et al., 1999]. Apart 
from the drug release pattern of the dosage form, it is the absorption, distribution, 
metabolization and excretion influence the in vivo drug concentration at the site of action. In 
view of the fact that interplay of the pharmacokinetic and pharmacodynamic parameters for 
a particular drug also has a noteworthy effect on the efficiency of the floating dosage form, 
in vivo evaluations appear to be requisite. Tracking the in vivo floating behavior and 
location of dosage form through GI tract providing a broad insight for formulating the 
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optimal floating drug delivery system could be established via radiography, gamma 
scintigraphy, gastroscopy, ultrasonography and magnetic resonance imaging. Considering 
the majority of the surveys in this case, not only the relevant correlation between in vivo and 
invitro assessments was confirmed but also effectiveness and reliability of these floating 
systems as an excellent strategy for controlled delivery of drugs was ascertained [Jain et al., 
2006; Ali et al., 2007; Wei & Zhao, 2008; Guguloth et al., 2011]. 
3.1.4.3. Drug release kinetic for the floating drug delivery systems 
Over the past few decades, the large variety of formulations devoted to floating drug 
delivery systems with varied physicochemical properties have become manifested which 
influence the drug release patterns of these formulations. In the same way as the ideal 
purpose of any drug delivery system is to maintain drug concentration in the blood or in 
target tissues at a desired value as long as possible, focusing on the drug release profiles to 
design a more systematic and intellectual floating system is has become even more rational. 
Accordingly, study of the drug release kinetics is often useful in obtaining one or two 
physically meaningful parameters which are employed for comparative purposes and 
relating the release parameter with important parameters such as bioavailability [Wagner, 
1969; Barzegar-Jalali et al., 2008; Dash et al., 2010].  
There are number of kinetic models, which described the overall release of drug from the 
dosage forms. Seeing as both qualitative and quantitative changes in a formulation could 
alter drug release and in vivo performance of the dosage form, developing tools that 
facilitate drug development by reducing the necessity of bio-studies is always desirable 
[Arifin et al., 2006; Javadzadeh, Hamedeyazdan et al., 2010]. Referring our former studies on 
drug release mechanisms from floating drug delivery systems, no a single kinetic model is 
customary for the floating dosage forms, even if the flotation strategies were the same 
[Adibkia et al., 2011]. Formulation variables, approaches in establishing formulation 
buoyancy and the kinetic models in analyzing the drug release data should have chosen 
parallel to present a suitable model fitting for these systems. In general, evaluating the 
mechanism behind drug release profile from floating dosage forms is complicated, and 
requires careful observance of the physicochemical properties of the dosage form. 
3.2. Mucoadhesive gastrointestinal drug delivery systems 
3.2.1. Introduction 
For years pharmaceutical scientists have been fascinated by the concept of bioadhesion. The 
term bioadhesion implies attachment of a drug carrier system to a specific biological 
location like epithelial tissue. This bioadhesion phenomenon is referred to as mucoadhesion 
if the adhesive attachment is to a mucus coat [Davidovich-Pinhas & Bianco-Peled, 2010]. 
Mucoadhesive drug delivery systems are used to localize a delivery device within the lumen 
to enhance the drug absorption in a site-specific manner since the luminal surface of the GI 
tract is a richly glycosylated tissue that presents considerable advantages in the use of 
formulations with mucoadhesive properties.  
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3.2.2. Factors affecting mucoadhesion  
Mucoadhesive characteristics are affected by a factor of both the bioadhesive polymer and 
the medium in which the polymer will exist in. The mucoadhesive properties of polymers 
themselves are concerned by diversity of factors such as molecular weight, flexibility, 
hydrogen bonding capacity, cross-linking density, charge, concentration, and hydration 
(swelling) of a polymer, which is briefly discussed below [Lahoti et al., 2011]. 
3.2.2.1. Polymer-related factors 
Molecular weight: In general, it has been revealed that the bioadhesive strength of a 
polymer increases with molecular weights above 100,000. 
Flexibility: Bioadhesion could be result of the diffusion of the polymer chains in the 
interfacial region. Then, containing of a substantial degree of flexibility is essential in order 
to get the desired entanglement with the mucus. In general, mobility and flexibility of 
polymers can be related to their viscosities and diffusion coefficients, where in the case of 
higher flexibility, greater diffusion into the mucus network was seen. 
Hydrogen bonding ability: It was found that for occurring of mucoadhesion, polymers 
must contain functional groups that are able to form hydrogen bonds. It was also showed 
that flexibility of the polymer is imperative to advance this hydrogen bonding potential. 
Cross-linking density: It gives the impressions that with increasing density of cross-linking, 
diffusion of water into the polymer network take place at a lower rate resulting an 
inadequate swelling of the polymer and a decreased rate of interpenetration between 
polymer and mucin. 
Charge: Nonionic polymers show a smaller degree of adhesion compared to anionic 
polymers. It was also shown that some cationic polymers display superior mucoadhesive 
properties, especially in a neutral or slightly alkaline medium. Furthermore, some cationic 
polymers such as chitosan that has high molecular weight have shown good adhesive 
properties. 
Concentration: In the lower concentration of the polymer, the number of penetrating 
polymer chains per unit volume of the mucus is small, and then the interaction between 
polymer and mucus is unstable. In general, the more concentrated polymer would result in 
a longer penetrating chain length and better adhesion. However, there is a critical 
concentration, above which the polymer generates an “unperturbed” situation due to a 
significantly coiled structure. As a result, the accessibility of the solvent to the polymer 
decreases, and chain penetration of the polymer is considerably reduced. Therefore, higher 
concentrations of polymers do not necessarily improve mucoadhesive properties and, in 
some cases, diminished effect was seen. 
Hydration (swelling): For any polymer in order to develop the interpenetration process 
between polymer and mucin, hydration is required to expand and create a proper 
“macromolecular mesh” of sufficient size, and also to induce mobility in the polymer chains. 
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3.2.2.2. Environmental factors 
The mucoadhesion of a polymer not only depends on its molecular properties, but also on 
the environmental factors adjacent to the polymer (pH, feed condition, and movement of the 
GI tissues while eating, drinking, or talking). Therefore, an optimum time period for the 
administration of the dosage form is necessary in order to avoid many of these interfering 
factors [Lahoti, Shep et al., 2011]. 
3.2.3. Polymers used for mucoadhesive drug delivery 
Polymers have played an important role in designing mucoadhesive drug delivery systems. 
Customarily, in these systems mucoadhesive polymers adhere to the mucin layer on the 
mucosal epithelium followed by a decrease in drug clearance rate from the GI absorption 
site, thereby increasing the time available for drug absorption [Rajput et al., 2010]. Polymers 
used in such system may have natural or synthetic origin. These polymers are classified as: 
3.2.3.1. Hydrophilic polymers  
These polymers are soluble in water. When put into an aqueous media, start to swell and 
subsequent dissolution of the matrix is occurred. The polyelectrolytes show superior 
mucoadhesive property in comparison with neutral polymers. Anionic polyelectrolytes, e.g. 
poly (acrylic acid) and carboxymethyl cellulose, have been broadly used for preparation of 
mucoadhesive formulations for their ability to exhibit strong hydrogen bonding with the 
mucin. Chitosan has been widely used as a cationic polyelectrolyte mucoadhesive polymer 
developing mucoadhesive property of these systems via electrostatic interactions with the 
negatively charged mucin chains. Moreover, these ionic polymers might have a drug 
delivery matrix exhibiting mucoadhesive property by developing ionic complex with the 
counter-ionic drug molecules. Alternatively, non-ionic polymers, such as poloxamer, 
hydroxypropyl methyl cellulose, methyl cellulose, poly (vinyl alcohol) and poly (vinyl 
pyrrolidone), have been used for mucoadhesive properties, as well. The hydrophilic 
polymers would be used as viscosity modifying/enhancing agents in the development of 
liquid ocular delivery systems for increasing the bioavailability of active agents by reducing 
the drainage of the administered formulations since they form viscous solutions when 
dissolved in water. Accordingly, a mucoadhesive drug delivery system would be 
established by these polymers when they are directly compressed in the presence of drugs. 
Polymers that are used frequently in ocular mucoadhesive delivery systems are usual 
polysaccharides and its derivatives like chitosan, methyl cellulose, hyaluronic acid, 
hydroxypropyl methylcellulose, hydroxypropyl cellulose, xanthan gum, gellan gum, guar 
gum, and carrageenan [Roy et al., 2009]. Besides, sustained release of drugs through these 
hydrophilic mucoadhesive polymers is accomplished in combination of the cationic 
cellulose derivatives (e.g. cationic hydroxyethyl celluloses) with various anionic polymers. 
3.2.3.2. Hydrogels 
Three-dimensionally crosslinked polymer chains have the ability to hold water within its 
porous structure forming hydrogels that are usually characterized with the presence of 
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hydrophilic functional groups like hydroxyl, amino and carboxyl groups bringing about the 
water holding capacity of these hydrogels. However, it is of value to note that with increase 
in the crosslinking density of hydrogels a decrease in the mucoadhesion would be 
inevitable. Preparation of the hydrogels by the condensation reaction of poly (acrylic acid) 
and sucrose pointed out an increase in the mucoadhesive property with the increase in the 
crosslinking density that was attributed to the rise in the poly (acrylic acid) chain density 
per unit area. In this regard, Wood and Peppas developed a system in which ethylene glycol 
chains were grafted on methacrylic acid hydrogels and were functionalized with wheat 
germ agglutinin. In this system the intestinal residence time of the delivery system was 
improved by binding of the wheat germ agglutinin with the specific carbohydrate moieties 
present in the intestinal mucosa. Mucoadhesive hydrogel based formulations not only 
have beneficial in drug targeting but also they are of use in improving the bioavailability 
of the poorly water soluble drug. Typically, Muller and Jacobs prepared a nanosuspension 
of buparvaquone, a poorly water soluble drug, by incorporating it within carbopol and 
chitosan based hydrogels [Muller & Jacobs, 2002]. Improved bioavailability of the drug in 
mucoadhesive delivery systems was determined when compared over the 
nanosuspension indicating the increased retention time of the delivery system within the 
GI tract. 
3.2.3.3. Thiolated polymers 
The mucoadhesive properties of the polymers (e.g. poly (acrylic acid) and chitosan) along 
with the paracellular uptake of the bioactive agents would be significantly improved 
through the presence of free thiol groups in polymeric skeleton which could help in the 
formation of disulphide bonds with that of the cysteine-rich sub-domains present in mucin. 
Some of the polymers including thiol groups are chitosan–iminothiolane, poly (acrylic 
acid)–cysteine, poly(acrylic acid)–homocysteine, chitosan–thioglycolic acid, chitosan–
thioethylamidine, alginate–cysteine, poly(methacrylic acid)–cysteine and sodium 
carboxymethylcellulose–cysteine [Roy, Pal et al., 2009]. 
3.2.3.4. Lectin-based polymers 
Lectins that are found in both animal and plant kingdom in addition to various 
microorganisms, are the proteins which have ability to reversibly bind with specific sugar or 
carbohydrate residues, providing with specific cyto-adhesive property for targeted delivery 
systems. Lectins extracted from Ulex europaeus I, soybean, peanut and Lens culinarius have 
demonstrated specific binding to the mucosa. Additionally, wheat germ agglutinin amongst 
other available lectins has shown limited immunogenic reactions exhibiting potential 
capacity to bind to the intestinal and alveolar epithelium as the favorable muccoadhesive 
polymer [Roy, Pal et al., 2009]. 
3.2.4. Methods of evaluation 
Mucoadhesive polymers and drug delivery systems can be evaluated by testing their 
adhesion strength by both in vitro and in vivo tests (Table 2). 
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In vitro / ex vivo methods In vivo methods
 Methods determining tensile strength  Use of radioisotopes 
 Methods determining shear stress  Use of gamma scintigraphy 
 Adhesion weight method  Use of pharmacoscintigraphy 
 Fluorescent probe method 
 Use of electron paramagnetic 
resonance (EPR) oximetry 
 Flow channel method  X ray studies 
 Mechanical spectroscopic method  Isolated loop technique 
 Falling liquid film method  
 Colloidal gold staining method  
 Viscometer method  
 Thumb method  
 Adhesion number  
 Electrical conductance  
 Swelling properties  
 In vitro drug release studies  
 Mucoretentability studies  
Table 2. Variety of in vitro / in vivo tests for evaluation of the adhesion strength in mucoadhesive 
sustems 
The GI transit time of these dosage forms could be measured by using one of the many radio 
opaque markers like barium sulphate which is coated to the bioadhesive dosage form so as 
to assess the GI transit by means of X-ray inspection. Both the distribution and retention can 
be studied by using of gamma scintigraphy. Using a non invasive technique to determine 
the transit time of mucoadhesive polymers is also popular and this could be imaged via 
labeling of the polymer with a gamma emitting nucleotide determining with the help of 
gamma scintigraphy. Another recent technique is to use magnetic resonance imaging to 
localize the point of release of thiolated polymers from dosage forms via the use of 
gadolinium determining by ascertaining the residence time of the fluorescently tagged 
thiomer on intestinal mucosa of rats after 3 hours [Tangri et al., 2011]). Although, 
considering the high cost, time consuming and ethical factors, these techniques are less 
usual common, evaluating the true mucoadhesive potential of the pharmaceutical dosage 
form is of essential [Shaikh et al., 2011]. 
Accordingly, there have been several successful attempts in identifying these putative 
bioadhesive or mucoadhesive materials using in vitro and in vivo tests but success usually 
has failed in translating to human studies in the stomach and small intestine [Sohrabi et al., 
2009; Movassaghian et al., 2011]. It may be due to the lack of correlation between mucosal 
conditions in the GI tract, and test models that are not in close proximity to the physiological 
circumstances. This phenomenon reinforces the note that appropriate testing methods are 
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required to be developed, with suitable compositions and mechanical forces. Moreover, the 
continuous production of mucous by the gastric mucosa to replace the mucous that is lost 
through peristaltic contractions seems to limit the potential of mucoadhesion as a 
gastroretentive force. On the contrary, colonic mucoadhesion due to the lower mucus 
turnover and sensitivity to mucus secretory stimulus is much more successful than small 
intestinal or gastric approaches, due to a thicker mucus layer and lower disruptive colonic 
motility.  
On the whole, it is suggested that this system normalizes the overall variations in drug GI 
transit time and allows for a more consistent performance of the formulations within and 
between individuals, improving the overall efficacy of drugs. However, the high turnover 
rate of gastric mucus and the probable local irritation by these drug formulations has 
remained challenging in this approach. 
3.3. Conclusion 
Ever since, the pharmaceutical concept of a dosage form seriously manipulate the stability, 
solubility, bioavailability, and other features of a medicine identifying these potential 
liabilities allows us to predict, control and avoid any complexities that may arise during 
pharmacotherapy. Hence, acquiring a clear notion of the assorted characteristics of drug 
delivery systems will not only allow proficient design of drug formulation, but also an 
improved in vitro and pre-clinical in vivo behavior of the drug, better in vitro - in vivo 
correlations, as well as opening new features in administrating drugs via novel drug 
delivery systems.  
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